期刊文献+

110例冠心病患者二级预防现况调查及随访分析 被引量:7

原文传递
导出
摘要 目的:对冠心病患者危险因素及二级预防的情况进行调查,了解冠心病二级预防的现状,探讨推广冠心病二级预防规范化治疗的效果。方法:对明确诊断为冠心病,并曾住院治疗的110例患者进行住院前及后续2年随访对危险因素的知晓及二级预防用药的情况。结果:110例冠心病患者与住院前比较,随访时对冠心病危险因素及二级预防,在知晓率、控制情况方面均有明显提高(P<0.05);住院时患者二级预防药物的使用是规范的(P<0.05),但除阿司匹林的服药率在随访2年时仍保持较高比例,与院内比率相近(P>0.05)外,冠心病患者未能长期坚持服用他汀类调脂药、β-受体阻滞剂、血管紧张素转化酶抑制剂或血管紧张素受体拮抗剂(P<0.05)3种药物。结论:冠心病二级预防规范化管理是提高冠心病患者二级预防依从性的重要手段之一。
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第4期314-315,共2页 Journal of Clinical Cardiology
  • 相关文献

参考文献6

  • 1刘新华.冠心病的二级预防思路[J].临床医药实践,2009,18(10X):740-742. 被引量:8
  • 2PUSKA P,VARTIAINEN E,TUOMILEHTO J,etal.Changes in premature deaths in Finland:success-ful long-term prevention of cardiovascular diseases[].Bulletin of the World Health Organization.1998
  • 3Berikai P,Meyer PM,Kazlauskaite R,et al.Gain in patients‘knowledge of diabetes management targets is associated with better glycemic control[].Diabetes Care.2007
  • 4Newby LK,LaPointe NM,Chen AY,et al.Long-termadherence to evidence-based secondary prevention therapies in coronary artery disease[].Circulation.2006
  • 5C Daly,F Clemens,JL Lopez-Sendon,L Tavazzi,E Boersma,N Danchin,F Delahaye,A Gitt,D Julian,D Mulcahy,W Ruzyllo,K Thygesen,F Verheugt,KM Fox.The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina[].European Heart Journal.2006
  • 6Stenestrand U,Wallentin L.Early statin treatment following acute myocardial infarction and 1-year survival[].Journal of the American Medical Association The.2001

二级参考文献3

共引文献7

同被引文献56

  • 1张晓峰,陈忠,汤涌,滕长青,文剑,王清波,陈宁宁,马根山,章晓国.早发冠心病患者的预后研究[J].中华临床医师杂志(电子版),2012,6(16):4744-4747. 被引量:1
  • 2宋丽芬,于瑞英,李瑞杰,李莉.“生命网”系统干预冠心病危险因素效益评估[J].心血管康复医学杂志,2005,14(3):203-204. 被引量:14
  • 3HE J, GU D, WU X,et al. Major causes of death a-mong men and women in China[J]. N Engl J Med,2005,353:1124 —1134.
  • 4GU D,GUPTA A, MUNTNER P, et al. Prevalenceof cardiovascular disease risk factor clustering amongthe adult population of China: results from the Inter-national Collaborative Study of Cardiovascular Diseasein Asia (Inter Asia) [J], Circulation.2005,112 : 658 —665.
  • 5ARMITAGE J. The safety of statins in clinical prac-tice[J]. Lancet,2007,370:1781-1790.
  • 6MCKENNEY J M,DAVIDSON M H, JACOBSONT A,et al. Final conclusions and recommendations ofthe national lipid association statin safety assessmenttask force[J]. Am J Cardiol,2006 *97 :89C—94.
  • 7刘遂心.冠心病康复/二级预防中国专家共识[A].中国康复医学会.中国康复医学会心血管病专业委员会换届暨学科发展高峰论坛会议资料[c].中国康复医学会:,2012:23.
  • 8Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other athero- sclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute [ J]. Circulation,2006 , 113 (19) :2363-72.
  • 9陈韵岱,吕树铮.GRACE研究国内外进展及其对急性冠脉综合征的临床指导意义[J].美国医学会杂志(中文版),2007,26(6):372-373. 被引量:1
  • 10Puska P,Vartiainen E,Tuomilehto J,Salomaa V,Nissinen A.Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bulletin of the World Health Organization . 1998

引证文献7

二级引证文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部